IndraLab

Statements

Bicalutamide inhibits TMPRSS2. 1 / 1

| 1

reach

"The suitability of these TMPRSS2 inhibitors including Bicalutamide to block TMPRSS2 for treatment of COVID-19 is currently being evaluated under clinical trial [70], [71], [72]."

33962011

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

Bicalutamide inhibits TMPRSS2. 1 / 1

INDRA sources:

Databases

Reading